ALK and non-small cell lung carcinoma: Several initial studies (ranging in size from 17 to 241 patients with the ALK rearrangement) suggested an increased risk of VTE in ALK-rearranged NSCLC, although findings were not consistent (VTE rates ranged from 8% to 47%, Table 3) [27,28,29,30,31,32,35,50].